{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:37:59Z","timestamp":1769560679423,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024149","name":"UCB Pharma Germany","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study is to evaluate possible long\u2010term effects of treatment with brivaracetam (BRV) on body weight in children with epilepsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Post hoc analysis of data from patients (aged 1\u2009month to &lt;17\u2009years) with \u22656\u2009months of BRV treatment in a long\u2010term, open\u2010label trial (N01266 [NCT01364597]). Outcomes included body weight and body mass index (BMI) over time (<jats:italic>z<\/jats:italic>\u2010score growth curves), and treatment\u2010emergent adverse events (TEAEs). Previous\/ongoing medical conditions that may affect body weight (gastrointestinal and metabolic\/nutritional disorders); concomitant antiseizure medications (ASMs) were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred nine patients (mean [standard deviation] age 7.9 [4.6] years) were analyzed. Most (154 [73.7%]) had focal\u2010onset seizures. At study initiation, median (range) BRV dose was 1.0 (0.4\u20137.5) mg\/kg\/day. Overall, 189 (90.4%) patients had a previous or ongoing medical condition (gastrointestinal disorders: 43 [20.6%]; metabolism\/nutritional disorders: 26 [12.4%]). Most patients followed <jats:italic>z<\/jats:italic>\u2010score curves for body weight and BMI during BRV treatment, although there were outliers in both directions. Incidences of appetite\/weight\u2010change TEAEs were low. Twenty\u2010three (11.0%) patients had a TEAE of decreased appetite and 14 (6.7%) had a TEAE of weight decreased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Long\u2010term adjunctive BRV was well tolerated in growing children with no indication of detrimental effects on body weight.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>Brivaracetam is an antiseizure medication (ASM) used to treat seizures in people with epilepsy. Some ASMs can lead to changes in people's appetite and weight. Knowing the effect a drug has on appetite and weight is particularly important in children. We looked at 209 children with epilepsy taking brivaracetam and studied changes in their body weight and body mass index over time. The number of reported side effects related to appetite or weight change was low. There was no apparent long\u2010term effect on their body weight, even when taking their medical history and use of other ASMs into account.<\/jats:p><\/jats:sec>","DOI":"10.1002\/epi4.13045","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T10:42:49Z","timestamp":1727865769000},"page":"2230-2240","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with brivaracetam has no apparent long\u2010term effects on body weight in pediatric patients with epilepsy"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4982-1092","authenticated-orcid":false,"given":"Florin I.","family":"Floricel","sequence":"first","affiliation":[{"name":"UCB Pharma  Monheim am Rhein Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2789-7176","authenticated-orcid":false,"given":"Paula E.","family":"Reichel","sequence":"additional","affiliation":[{"name":"Institute of Nutritional Medicine University of L\u00fcbeck and University Hospital Schleswig\u2010Holstein  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Dickson","sequence":"additional","affiliation":[{"name":"UCB Pharma  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Fleyshman","sequence":"additional","affiliation":[{"name":"UCB Pharma  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8145-2767","authenticated-orcid":false,"given":"Christoph","family":"Reichel","sequence":"additional","affiliation":[{"name":"UCB Pharma  Monheim am Rhein Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan\u2010Peer","family":"Elshoff","sequence":"additional","affiliation":[{"name":"UCB Pharma  Monheim am Rhein Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00505-2"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ncp.10274"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2009.03.010"},{"key":"e_1_2_11_5_1","first-page":"47","article-title":"Evaluation of the metabolic syndrome criteria and body composition in ambulatory children with epilepsy using sodium valproate and carbamazepine in southern Iran: a case\u2010control study","volume":"14","author":"Inaloo S","year":"2020","journal-title":"Iran J Child Neurol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02206.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.nrl.0000202599.21758.9a"},{"key":"e_1_2_11_8_1","unstructured":"European Medicines Agency.BRIVIACT\u00ae (brivaracetam) Summary of Product Characteristics.2023. [cited 2024 Jan 29]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/briviact\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_9_1","unstructured":"Food and Drug Administration.BRIVIACT\u00ae (brivaracetam) Full Prescribing Information.2023. [cited 2024 Jan 29]. Available from:https:\/\/www.briviact.com\/briviact\u2010PI.pdf"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17754"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00332-y"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17187"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12875"},{"key":"e_1_2_11_14_1","first-page":"1","article-title":"CDC growth charts: United States","volume":"314","author":"Kuczmarski RJ","year":"2000","journal-title":"Adv Data"},{"key":"e_1_2_11_15_1","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","volume":"246","author":"Kuczmarski RJ","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"e_1_2_11_16_1","first-page":"1","article-title":"Centers for disease control prevention. Use of World Health Organization and CDC growth charts for children aged 0\u201359 months in the United States","volume":"59","author":"Grummer\u2010Strawn LM","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.043497"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3809"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2016.04.008"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.12.012"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.11.039"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00800.x"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(02)00505-2"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114522003786"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.003798"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.182623"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.13045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:21:52Z","timestamp":1733944912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.13045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/epi4.13045"],"URL":"https:\/\/doi.org\/10.1002\/epi4.13045","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}